Abstract
To date, the majority of trials on chronic lymphocytic leukemia (CLL) have focused on patients considerably younger than the median age of onset for CLL. As a result, no definitive treatment exists for elderly patients, especially less medically fit patients. Even today, most physicians consider chlorambucil to be an appropriate option for elderly CLL patients. Practices, however, have subsequently changed following the results of several Phase III trials. Given the potential of these new immunotherapy regimens, selecting the right treatment for elderly CLL patients is still challenging.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.